Document Type : Original Article
Authors
- Keivan Basiri 1
- Maryam Alizadeh 2
- Behnaz Ansari 1
- Majid Ghasemi 1
- Mohsen Kheradmand 3
- Maryam Sedghi 4
1 Isfahan Neuroscience Research Center, Al-Zahra Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
2 Department of Neurology, School of Medicine, Al-Zahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran
3 Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
4 Medical Genetics Laboratory, Al-Zahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran
Abstract
Background: Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are inherited X-linked disorders resulting from alterations in the dystrophin gene. Genotype-phenotype matching studies have revealed a link between disease severity, the amount of muscle dystrophin, and the extent of mutation/deletion on the dystrophin gene. This study aimed to assess the relationship between genetic alterations in the dystrophin gene and the clinical status of patients with dystrophinopathies among the Iranian population.
Methods: This cross-sectional study examined 54 patients with muscle weakness caused by abnormalities in the dystrophin gene at a hospital affiliated to Isfahan University of Medical Sciences, Isfahan, Iran, in 2021. The participants’ demographic information, including age, family history of muscle dystrophies, and family history of other medical diseases as well as the type of muscular dystrophy were recorded. Furthermore, the number and region of deleted exons based on dystrophy types were also evaluated using multiplex ligation-dependent probe amplification (MLPA). The patients’ gaits were also assessed as using a wheelchair, the presence of waddling gaits, or toe gaits. The patients’ clinical status and the coexistence of pulmonary, bulbar, and mental conditions were also examined and compared between the two groups of dystrophinopathies.
Results: In this study, 54 patients with dystrophinopathy with the mean age of 16.63 ± 12.10 years were evaluated, of whom 22 (40.7%) and 30 (55.6%) patients were classified as BMD and DMD, respectively.
The most affected regions with deleted exons were exons 45-47 (n = 5) and 45-48 (n = 4) in patients with BMD, while exons 45, 48-52, 51-55, and 53 (2 cases per exon) were the most common affected exons in patients with DMD. Further analyses revealed that deletions in exons 45-47 and 51-55 were significantly associated with older and younger ages at the onset of becoming wheelchair-bound in patients with dystrophy, respectively. The hotspot range in both BMD and DMD was within exons 45-55 (n = 15 for each group); 63% of the patients had alterations on the dystrophin gene within this range [30 patients (68.18%) in the BMD group, 15 patients (53.57%) in the DMD group].
Conclusion: Exon deletion was the most common genetic alteration in patients with dystrophinopathies. No significant difference was observed between DMD and BMD regarding the number of deleted exons. Deletions in exons 45-47 and 51-55 were linked to later and earlier onset of becoming wheelchair-bound, respectively.
Keywords
- Yiu EM, Kornberg AJ. Duchenne muscular dystrophy. J Paediatr Child Health 2015; 51(8): 759-64.
- Duan D, Goemans N, Takeda S, Mercuri E, Aartsma-Rus A. Duchenne muscular dystrophy. Nat Rev Dis Primers 2021; 7(1): 14.
- Falzarano MS, Scotton C, Passarelli C, Ferlini A. Duchenne muscular dystrophy: From diagnosis to therapy. Molecules 2015; 20(10): 18168-84.
- Verhaart IEC, Aartsma-Rus A. Therapeutic developments for Duchenne muscular dystrophy. Nat Rev Neurol 2019; 15(7): 373-86.
- Ryder S, Leadley RM, Armstrong N, Westwood M, de Kock S, Butt T, et al. The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: An evidence review. Orphanet J Rare Dis 2017; 12(1): 79.
- Crisafulli S, Sultana J, Fontana A, Salvo F, Messina S, Trifiro G. Global epidemiology of Duchenne muscular dystrophy: An updated systematic review and meta-analysis. Orphanet J Rare Dis 2020; 15(1): 141.
- El-Aloul B, Speechley KN, Wei Y, Wilk P, Campbell C. Fatigue in young people with Duchenne muscular dystrophy. Dev Med Child Neurol 2020; 62(2): 245-51.
- Nicolas A, Raguenes-Nicol C, Ben YR, Ameziane-Le HS, Cheron A, Vie V, et al. Becker muscular dystrophy severity is linked to the structure of dystrophin. Hum Mol Genet 2015; 24(5): 1267-79.
- Capitanio D, Moriggi M, Torretta E, Barbacini P, De Palma S, Vigano A, et al. Comparative proteomic analyses of Duchenne muscular dystrophy and Becker muscular dystrophy muscles: Changes contributing to preserve muscle function in Becker muscular dystrophy patients. J Cachexia Sarcopenia Muscle 2020; 11(2): 547-63.
- Eisen B, Ben JR, Cuttitta AJ, Mekies LN, Shemer Y, Baskin P, et al. Electrophysiological abnormalities in induced pluripotent stem cell-derived cardiomyocytes generated from Duchenne muscular dystrophy patients. J Cell Mol Med 2019; 23(3): 2125-35.
- Gordish-Dressman H, Willmann R, Dalle PL, Kreibich A, van Putten M, Heydemann A, et al. "Of Mice and Measures": A project to improve how we advance Duchenne muscular dystrophy therapies to the clinic. J Neuromuscul Dis 2018; 5(4): 407-17.
- Bendixen RM, Morgenroth LP, Clinard KL. Engaging participants in rare disease research: A qualitative study of Duchenne muscular dystrophy. Clin Ther 2016; 38(6): 1474-84.
- Vengalil S, Preethish-Kumar V, Polavarapu K, Mahadevappa M, Sekar D, Purushottam M, et al. Duchenne muscular dystrophy and Becker muscular dystrophy confirmed by multiplex ligation-dependent probe amplification: Genotype-phenotype correlation in a large cohort. J Clin Neurol 2017; 13(1): 91-7.
- Frank DE, Schnell FJ, Akana C, El-Husayni SH, Desjardins CA, Morgan J, et al. Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy. Neurology 2020; 94(21): e2270-82.
- Vieira NM, Elvers I, Alexander MS, Moreira YB, Eran A, Gomes JP, et al. Jagged 1 rescues the Duchenne muscular dystrophy phenotype. Cell 2015; 163(5): 1204-13.
- Duan D. Systemic AAV micro-dystrophin gene therapy for Duchenne muscular dystrophy. Mol Ther 2018; 26(10): 2337-56.
- Duan D. Micro-dystrophin gene therapy goes systemic in Duchenne muscular dystrophy patients. Hum Gene Ther 2018; 29(7): 733-6.
- Mori-Yoshimura M, Mitsuhashi S, Nakamura H, Komaki H, Goto K, Yonemoto N, et al. Characteristics of Japanese patients with Becker muscular dystrophy and intermediate muscular dystrophy in a Japanese National Registry of Muscular Dystrophy (Remudy): Heterogeneity and clinical variation. J Neuromuscul Dis 2018; 5(2): 193-203.
- Okubo M, Goto K, Komaki H, Nakamura H, Mori-Yoshimura M, Hayashi YK, et al. Comprehensive analysis for genetic diagnosis of Dystrophinopathies in Japan. Orphanet J Rare Dis 2017; 12(1): 149.
- Suh MR, Lee KA, Kim EY, Jung J, Choi WA, Kang SW. Multiplex ligation-dependent probe amplification in X-linked recessive muscular dystrophy in Korean subjects. Yonsei Med J 2017; 58(3): 613-8.
- Danieli GA, Mioni F, Muller CR, Vitiello L, Mostacciuolo ML, Grimm T. Patterns of deletions of the dystrophin gene in different European populations. Hum Genet 1993; 91(4): 342-6.
- Muntoni F, Torelli S, Ferlini A. Dystrophin and mutations: One gene, several proteins, multiple phenotypes. Lancet Neurol 2003; 2(12): 731-40.
- Juan-Mateu J, Gonzalez-Quereda L, Rodriguez MJ, Baena M, Verdura E, Nascimento A, et al. DMD mutations in 576 dystrophinopathy families: A step forward in genotype-phenotype correlations. PLoS One 2015; 10(8): e0135189.
- Yun U, Lee SA, Choi WA, Kang SW, Seo GH, Lee JH, et al. Clinical and genetic spectra in patients with dystrophinopathy in Korea: A single-center study. PLoS One 2021; 16(7): e0255011.
- Lim KRQ, Nguyen Q, Yokota T. Genotype-phenotype correlations in Duchenne and Becker muscular dystrophy patients from the Canadian Neuromuscular Disease Registry. J Pers Med 2020; 10(4): 241.
)